- Galmed Pharmaceuticals (NASDAQ:GLMD) shares fell 8.41% after Raymond James Analyst Steven Seedhouse downgraded the ratings of the biotechnology company to Market Perform from Outperform without a price target.
- The company had reported Q1 GAAP EPS of -$0.24, beats by $0.08.
- H.C. Wainwright had downgraded the Israel-based company to Neutral earlier in the month, citing, among other things, uncertainty in its research into liver disease, non-alcoholic steato-hepatitis (NASH).
Galmed Pharmaceuticals shares fall after downgrade by Raymond James analyst
Recommended For You
About GLMD Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| GLMD | - | - |
| Galmed Pharmaceuticals Ltd. | ||